Who Owns Palisade Bio Stock?
NASDAQ: PALIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 100.50%
- Institutions (% of float)
- 105.21%
- Held by insiders
- 4.48%
- Institutional holders
- 150
- Institutions 95.5%
- Insiders 4.5%
- Public and other 0.0%
Who owns Palisade Bio stock?
Institutional investors own about 100.5% of Palisade Bio's shares, spread across 150 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.48% of PALI.
The largest institutional holders are Soleus Capital Management, L.P. (8.36%), Ameriprise Financial, Inc. (8.13%) and B Group, Inc. (6.37%). Together, the top 10 institutions control 57.2% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their PALI positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PALI
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Soleus Capital Management, L.P. | 15.00M | 8.36% | +14.8% |
| Ameriprise Financial, Inc. | 14.57M | 8.13% | +31.5% |
| B Group, Inc. | 11.41M | 6.37% | 0.0% |
| Blackrock Inc. | 11.10M | 6.19% | +6.3% |
| Janus Henderson Group Ltd. | 10.69M | 5.96% | 0.0% |
| Octagon Capital Advisors LP | 10.28M | 5.73% | 0.0% |
| Perceptive Advisors Llc | 8.43M | 4.70% | 0.0% |
| Vanguard Capital Management LLC | 7.89M | 4.40% | +357.9% |
| RA Capital Management, L.P. | 7.12M | 3.97% | 0.0% |
| Franklin Templeton, Inc. | 6.07M | 3.39% | +4.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PALI
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 4.03M | 2.25% |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 3.14M | 1.75% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 2.12M | 1.18% |
| abrdn Life Sciences Investors | 1.91M | 1.07% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.72M | 0.96% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.62M | 0.90% |
| iShares Trust-iShares Russell 2000 Value ETF | 1.12M | 0.63% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 843.88K | 0.47% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 787.55K | 0.44% |
| TIAA-CREF Funds-Nuveen Equity Index Fund | 773.20K | 0.43% |
Frequently asked questions
Who is the largest shareholder of Palisade Bio?
Soleus Capital Management, L.P. is the largest institutional shareholder of PALI, owning 8.36% of shares outstanding (15.00M shares) as of its latest 13F filing.
What percentage of Palisade Bio is owned by institutions?
Institutions own about 100.5% of PALI shares and 105.2% of the public float.
How much of Palisade Bio do insiders own?
Insiders, such as officers and directors, own about 4.48% of PALI shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.